Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off

The biotech sector is already buzzing with retail investor interest as the new year begins. Here’s a look at the top three biotech stocks driving conversations on Stocktwits based on message volume jumps on the first trading day of 2025:

Carmell Corp (CTCX): +58,100% Message Volume

Regenerative medicine biotech Carmell Corp surged into the spotlight after announcing an acquisition deal with PMGC Holdings’ Elevai Skincare subsidiary. The transaction includes $1.1 million in Carmell stock, $57,000 in cash, and contingent earnouts linked to Elevai’s product sales and revenue milestones. 

Carmell expects to acquire Elevai’s skincare and haircare portfolio, including a commercial team and inventory with $2.5 million in trailing revenue. 

Shares rocketed 148% on Thursday but saw some profit-taking early on Friday. Carmell’s stock lost roughly 80% last year.

Mustang Bio (MBIO): +27,200% Message Volume

Mustang Bio shares climbed 18% on Thursday and gained further in Friday’s pre-market, despite no apparent catalyst. 

In November, the company secured an extension from Nasdaq to meet compliance requirements and received FDA Orphan Drug Designation for MB-108, an oncolytic virus treatment for malignant glioma. 

While the stock fell nearly 85% in 2024, recent developments have sparked renewed optimism among investors.

Revelation Biosciences (REVB): +9,150% Message Volume

Revelation Biosciences rose 42% on Thursday before sliding in Friday’s pre-market session without any catalyst. 

Retail buzz centers on its investigational therapy, Gemini, which received FDA clearance last month for a Phase 1b trial targeting chronic kidney disease patients. 

However, concerns around the company’s cash burn and financing moves have tempered investor enthusiasm. REVB shares dropped over 90% in 2024, leaving the stock a speculative favorite entering 2025.

For updates and corrections, email newsroom[at]stocktwits[dot]com.